Corporate Member Update: Gilead-FDA APPROVES TRODELVY®
Corporate Member Update: Gilead-FDA APPROVES TRODELVY®
TRODELVY®
April, 2021
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
To read the full press release, please click here.